Related Experiment Video
Updated: Oct 9, 2025
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
miR-6315 Attenuates Methotrexate Treatment-Induced Decreased Osteogenesis and Increased Adipogenesis Potentially
Ya-Li Zhang1, Liang Liu1, Yu-Wen Su1
1UniSA Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.
Abstract:
Methotrexate (MTX) treatment for childhood malignancies has shown decreased osteogenesis and increased adipogenesis in bone marrow stromal cells (BMSCs), leading to bone loss and bone marrow adiposity, for which the molecular mechanisms are not fully understood. Currently, microRNAs (miRNAs) are emerging as vital mediators involved in bone/bone marrow fat homeostasis and our previous studies have demonstrated that miR-6315 was upregulated in bones of MTX-treated rats, which might be associated with bone/fat imbalance by directly targeting Smad2. However, the underlying mechanisms by which miR-6315 regulates osteogenic and adipogenic differentiation require more investigations. Herein, we further explored and elucidated the regulatory roles of miR-6315 in osteogenesis and adipogenesis using in vitro cell models. We found that miR-6315 promotes osteogenic differentiation and it alleviates MTX-induced increased adipogenesis. Furthermore, our results suggest that the involvement of miR-6315 in osteogenesis/adipogenesis regulation might be partially through modulating the TGF-β/Smad2 signalling pathway. Our findings indicated that miR-6315 may be important in regulating osteogenesis and adipogenesis and might be a therapeutic target for preventing/attenuating MTX treatment-associated bone loss and marrow adiposity.
Insights
MicroRNA-6315 (miR-6315) promotes bone formation and reduces fat buildup in bone marrow cells, potentially preventing bone loss caused by methotrexate treatment.
Area of Science:
- Molecular Biology
- Cell Biology
- Endocrinology
Background:
- Methotrexate (MTX) treatment for childhood cancers disrupts bone marrow stromal cells (BMSCs), decreasing bone formation and increasing fat accumulation.
- The molecular mechanisms underlying MTX-induced bone loss and marrow adiposity are not fully understood.
- MicroRNAs (miRNAs) are key regulators of bone and fat homeostasis.
Purpose of the Study:
- To investigate the regulatory role of miR-6315 in osteogenic and adipogenic differentiation.
- To elucidate the mechanisms by which miR-6315 influences bone/fat balance in vitro.
- To explore miR-6315 as a potential therapeutic target for MTX-associated bone complications.
Main Methods:
- In vitro cell models were utilized to study miR-6315's effects on osteogenesis and adipogenesis.
- Analysis of miR-6315 expression in response to MTX treatment.
- Investigation of the TGF-β/Smad2 signaling pathway's involvement.
Main Results:
- miR-6315 was found to promote osteogenic differentiation.
- miR-6315 alleviated MTX-induced increases in adipogenesis.
- The regulatory effects of miR-6315 on bone and fat differentiation may involve modulation of the TGF-β/Smad2 pathway.
Conclusions:
- miR-6315 plays a significant role in regulating osteogenesis and adipogenesis.
- miR-6315 may serve as a therapeutic target to prevent or reduce bone loss and marrow adiposity associated with MTX treatment.
- Further research is warranted to fully understand miR-6315's therapeutic potential.
